A multi-year study has found that rheumatoid arthritis appears to begin years before joint pain or stiffness, with sweeping immune changes unfolding silently in people who carry RA‑linked antibodies. By tracking these at‑risk individuals over seven years, researchers documented systemic inflammation, immune cell dysfunction and epigenetic reprogramming, findings that could support earlier detection and prevention efforts.
Rheumatoid arthritis (RA), a chronic autoimmune disease that causes painful joint inflammation and damage, appears to start long before symptoms emerge, according to new research based on work from the Allen Institute and collaborators.
The study team reports in Science Translational Medicine that people at higher risk for RA are already experiencing a largely invisible autoimmune process well before their first aches or stiffness. Using detailed immune profiling, the researchers mapped how the disease process builds over time in this preclinical phase.
In a seven‑year, multi‑institution study, scientists from the Allen Institute, the University of Colorado Anschutz Medical Campus (CU Anschutz), the University of California San Diego and the Benaroya Research Institute followed individuals who carried anti‑citrullinated protein antibodies (ACPA). These antibodies are well‑established biomarkers for increased RA risk. Over the course of the study, the team identified widespread inflammation and immune cell abnormalities resembling those seen in people with established RA.
According to the Allen Institute and a report in ScienceDaily, the researchers observed signs of systemic inflammation throughout the body, not just in the joints, mirroring the body‑wide inflammatory state often found in active RA.
Key immune disruptions included B cells in a pro‑inflammatory state and an expansion of T helper cells, especially a subset resembling so‑called Tfh17‑like cells. These T cells help coordinate immune responses, including the production of autoantibodies that can attack healthy tissue, and their overactivity may help explain why the immune system begins targeting the body’s own joints.
The team also found evidence of cellular "reprogramming." Even naive T cells, which normally have not yet encountered pathogens or other threats, showed epigenetic changes – shifts in how genes are turned on and off without altering the underlying DNA sequence. These changes suggest the cells are being primed for an autoimmune response before any symptoms appear.
In addition, circulating monocytes – a type of white blood cell – were producing high levels of inflammatory molecules. The researchers report that these blood‑borne cells closely resembled the macrophages seen in inflamed joint tissue from RA patients, indicating that a joint‑like inflammatory program may already be present in the blood of at‑risk individuals.
"Overall, we hope this study raises awareness that rheumatoid arthritis begins much earlier than previously thought and that it enables researchers to make data‑driven decisions on strategies to disrupt disease development," said Mark Gillespie, Ph.D., an assistant investigator at the Allen Institute and a co‑senior author on the study, in a statement released by the institute.
Co‑senior author Kevin Deane, M.D./Ph.D., of CU Anschutz, added in the same release: "We expect that going forward the findings from this study will support additional studies to identify ways to better predict who will get RA, identify potential biologic targets for preventing RA as well as identify ways to improve treatments for those with existing RA."
Researchers and the Allen Institute’s summary say these insights reveal new biomarkers and immune signatures that could help identify which at‑risk individuals are most likely to develop RA. While more work is needed before routine screening or preventive therapies can be implemented, the study supports a shift toward detecting and potentially intervening in RA during its hidden early phase, with the goal of preventing joint damage and long‑term disability.
